Literature DB >> 26328119

Bilateral testicular germ cell tumors.

Haşmet Sarıcı1, Onur Telli1, Muzaffer Eroğlu1.   

Abstract

Testicular cancer represents 1% to 1.5% of neoplasias in males and 5% of urologic tumors in general. The incidence of bilateral testicular tumors is 1-5%. Approximately one third of the cases are diagnosed as synchronous, while the other two thirds are diagnosed as metachronous tumors. Additionally, 5% of all patients diagnosed with testicular cancer may have contralateral intratubular germ cell neoplasia and may develop a contralateral germ cell tumor. However, few data are available regarding bilateral testicular germ cell tumors (BTGCTs). In this review, we aim to provide an overview of the incidence, pathological features and clinical outcomes.of BTGCTs.

Entities:  

Keywords:  Bilateral testicular cancer; bilateral testicular germ cell tumor; testicular germ cell tumor

Year:  2013        PMID: 26328119      PMCID: PMC4548607          DOI: 10.5152/tud.2013.062

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  35 in total

Review 1.  Bilateral testicular germ cell tumours: a systematic review.

Authors:  Stenio de Cassio Zequi; Walter Henriques da Costa; Thiago B M Santana; Ricardo L Favaretto; Carlos A R Sacomani; Gustavo C Guimaraes
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

Review 2.  Is biopsy of the contralateral testis necessary in patients with germ cell tumors?

Authors:  H W Herr; J Sheinfeld
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  Bilateral testicular germ cell tumors: a report of 20 cases.

Authors:  K Scheiber; D Ackermann; U E Studer
Journal:  J Urol       Date:  1987-07       Impact factor: 7.450

4.  Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.

Authors:  H von der Maase; M Rørth; S Walbom-Jørgensen; B L Sørensen; I S Christophersen; T Hald; G K Jacobsen; J G Berthelsen; N E Skakkebaek
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-29

Review 5.  Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich.

Authors:  Marcus Hentrich; Norbert Weber; Thorsten Bergsdorf; Bernhard Liedl; Reiner Hartenstein; Arthur Gerl
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

6.  Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study.

Authors:  T Westergaard; J H Olsen; M Frisch; N Kroman; J W Nielsen; M Melbye
Journal:  Int J Cancer       Date:  1996-05-29       Impact factor: 7.396

7.  Second primary germ cell tumors in patients with seminoma of the testis.

Authors:  A G Cockburn; D Vugrin; M Batata; S Hajdu; W F Whitmore
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

8.  Bilateral testicular germ cell tumors in Turkey: increase in incidence in last decade and evaluation of risk factors in 30 patients.

Authors:  Bulent Akdogan; Akdogan Bulent; Rauf Taner Divrik; Divrik Rauf Taner; Tolga Tombul; Tombul Tolga; Sertac Yazici; Yazici Sertac; Celik Tasar; Tasar Celik; Ferruh Zorlu; Zorlu Ferruh; Haluk Ozen; Ozen Haluk
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

9.  Risk of bilateral testicular germ cell cancer in Denmark: 1960-1984.

Authors:  A Osterlind; J G Berthelsen; N Abildgaard; S O Hansen; H Hjalgrim; B Johansen; J Munck-Hansen; L H Rasmussen
Journal:  J Natl Cancer Inst       Date:  1991-10-02       Impact factor: 13.506

Review 10.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

View more
  4 in total

Review 1.  Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Authors:  Bilal A Siddiqui; Miao Zhang; Louis L Pisters; Shi-Ming Tu
Journal:  Transl Androl Urol       Date:  2020-01

2.  Educational Case: Classic seminoma of the testis.

Authors:  Danielle K Stamer; Jennifer L Clark
Journal:  Acad Pathol       Date:  2022-05-31

3.  Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma: a population-based study.

Authors:  Huihuang Li; Zhiyong Cai; Renyu Liu; Jiao Hu; Jinbo Chen; Xiongbing Zu
Journal:  Transl Androl Urol       Date:  2021-01

4.  Development and validation of a nomogram to predict survival in patients with metastatic testicular germ cell tumors.

Authors:  Dong-Dong Yu; Dong Hui; Wei-Kang Chen; Yun-Bei Xiao; Zhi-Gang Wu; Qin-Quan Wang; Chao-Feng Zhou; Zhi-Xia Chen; Cheng-Di Li; Jian Cai
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.